Posted by Michael Wonder on 14 Sep 2024
US FDA grants RPD designation to Senhwa Biosciences silmitasertib for paediatric neuroblastoma
13 September 2024 - Senhwa Biosciences today announced that its new drug silmitasertib (CX-4945) was granted a rare paediatric disease designation by US FDA for the treatment of neuroblastoma.
This is the recognition obtained again after silmitasertib received rare paediatric disease designation in medulloblastoma from the FDA in July 2020, demonstrating the great potential of silmitasertib in the development of treatments for rare paediatric cancers.
